Postsurgical Pembrolizumab and Chemo, With or Without Radiotherapy, Falls Short in Phase 3 Trial for Newly Diagnosed, High-Risk Endometrial Cancer - AJMC.com Managed Markets Network
Postsurgical Pembrolizumab and Chemo, With or Without Radiotherapy, Falls Short in Phase 3 Trial for Newly Diagnosed, High-Risk Endometrial Cancer AJMC.com Managed Markets Network
Ovarian clear cell carcinoma (OCCC) is a less common subtype accounting for approximately 5% of all epithelial ovarian cancers (EOCs). Clinical experience and research findings confirm the remarkable differences in …